Navigation Links
RXi Pharmaceuticals Announces CEO Interview
Date:7/18/2013

WESTBOROUGH, Mass., July 18, 2013 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals, completed an interview with Keith Markey, Ph.D, Equities Analyst with Griffin Securities. During this interview, Dr. Cauwenbergh discusses next steps in the evolution of the company in relation to its anti-scarring compound, RXI-109, and other self-delivering RNAi (sd-rxRNA®) opportunities.

A replay of the interview is available on the "Investors" section of the company's website, www.rxipharma.com/investors/events.        

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTCQX: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012.  For more information, please visit www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks, and uncertainties: risks that RXi may not be able to successfully develop its candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to control timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.


'/>"/>
SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cree, Intuitive Surgical, Alexion Pharmaceuticals, Roche and Onyx Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
2. Abuse-Deterrent Formulations of Purdues OxyContin and Endo Pharmaceuticals Opana ER Have Not Increased PCPs Comfort When Prescribing These Products for Chronic Pain
3. Valeant Pharmaceuticals To Announce 2013 Second Quarter Results On August 7, 2013
4. GW Pharmaceuticals to Report Q3 2013 Results and Host Conference Call on 5 August, 2013
5. RXi Pharmaceuticals Announces Positive Data in Second Phase 1 Multi-Dose Study
6. UCBs Kremers Urban Pharmaceuticals Inc. receives FDA approval for extended release methylphenidate hydrochloride
7. Tris Pharmas Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution
8. Breckenridge Announces Dismissal of Various Lawsuits Against Macoven Pharmaceuticals in Return for Macovens Discontinuance of Certain Products
9. Kinex Pharmaceuticals Will Take the Lead in the Orascovery Program Development in China
10. Actinium Pharmaceuticals Clinical Results Featured at a United Nations Forum
11. Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... LONDON , May 24, 2016   ... primary endpoints demonstrating non-inferiority in overall bowel cleansing and superiority ... c leansing of ... http://photos.prnewswire.com/prnh/20130829/633895-a ) , Norgine B.V. today announced ... (1 litre PEG and ascorbate bowel preparation) versus standard 2 litre ...
(Date:5/24/2016)... Marziani has joined VMS BioMarketing as senior vice president of sales, announced Andrea ... Marziani will lead the company,s business development and sales team, exploring new opportunities for ... - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... May 24, 2016 Dutch surgeons have launched ... around the world and treat patients on a global scale. Medical ... , Asia and the US have already ... messaging and networking in a totally secure environment. Education  ... war zone working together with a surgeon at Harvard to treat ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... The World Molecular Imaging ... Molecular Imaging.” The focus of ADDMI-IG will be geared towards how using molecular ... issues. Through ADDMI-IG WMIS will provide a platform for productive discussions about the ...
(Date:5/25/2016)... ... 2016 , ... DKT International, one of the largest private ... to release their 2015 global impact data. In 2015, DKT served over 30 ... and 3.8 million unsafe abortions across 21 countries worldwide. , “We are ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... solutions to industries ranging from medical and pharmaceutical, to food and HVAC facilities. ... well as on-site training. , For medical applications, Afrimesure offers a variety ...
(Date:5/25/2016)... ... , ... Casa Velas, an adults-only boutique hotel in Puerto Vallarta, Mexico, introduces ... wellness suites . The two 1,350 sq. ft. suites which debuted in late ... insuite amenities, from a custom soap selection and in-suite exercise kit to a personal ...
(Date:5/25/2016)... CA (PRWEB) , ... May 25, 2016 , ... The ... of Nursing and Health Professions. She will lead a team of more than 100 ... Baker will begin her role as dean in late August. , Baker comes to ...
Breaking Medicine News(10 mins):